Moncef Jendoubi, Ph.D., DES, Founder, President, CEO, CSO
Dr Jendoubi holds a MS in Genetics, a MS in Biochemistry, a PhD in Molecular Biology, a “Doctorat D’Etat Es Sciences” in Immunology, a special Diploma in bacteriology from the University of Paris, and was trained at the Pasteur Institute, where he held the position of Associate Professor. In 1987, Dr Jendoubi joined the National Institutes of Health as Visiting Professor, and became Chief of the Genetics and Molecular Immunology Section in 1990. During his career at the NIH he developed research aimed at understanding cell-cell communication pathways using genetically engineered mice and molecular genetics. He is the author of dozens of publications and patents. Throughout his scientific and entrepreneurial career, he founded and co-founded several successful biotech companies in the diagnostic and therapeutic field. He founded and managed Milagen Inc., from its inception to a fully integrated diagnostic company. Dr Jendoubi has also co-founded Abnova Corporation in Taipei, Taiwan in 2001, Phenotype Pharmaceuticals in 2004, and ServaCare in 2012. Dr Jendoubi is currently an active member of the American Society of Clinical Oncology (ASCO), the American Association of Clinical Chemistry (AACC), and Associate Member of the Early Detection Research Network of the National Cancer Institute (EDRN-NCI-NIH).
Heinz Bodenmueller, VP of Business Development and Strategy
Dr Bodenmueller is a renowned leader in the industry of diagnostics and therapeutics where he spent over 25 years. He started his career at Boehringer Mannheim GmbH, Research Center Tutzing, Germany (1987-98) as a manager in the department of New Diagnostics and Oncology. Then he moved to Roche Diagnostics Research Center in Penzberg, Germany (1989-2011) as Director responsible for Oncology / New Markers, for Laboratory Diagnostics.
During his tenure at Roche Diagnostics, he held leadership positions in managing internal and external research projects in the diagnostic division. In particular, Dr Bodenmueller was responsible for the development of several products that are currently generating millions of dollars in revenues, and are considered as gold standard products in the industry for the detection of cancers.
Author and co-author to over 60 peer-reviewed articles, Dr Bodenmueller received a diploma of biochemistry in 1973 from the University of Bern, and a PhD in biochemistry and organic chemistry in 1976 from the Max-Planck Institute of Medical Research, University of Heidelberg in Germany.
Kurt T Mulville, Intellectual Property Counsel
Admitted to practice before the USPTO, Mr Mulville’s law expertise is devoted to intellectual property, with a principal focus on litigation, counseling and opinions. Mr Mulville also has over 25 years of experience in developing patent portfolios and patent strategies for start-up companies in highly competitive environments in the field of biomedical technologies such as pharmaceutical compounds, advanced medical and diagnostic devices, genomics, and transgenics. In addition, he is frequently retained to render opinions and perform IP due diligence analyses for venture capital and other start-up funding organizations.
Mr Mulville received a double major in Chemistry and Biology from UC Irvine in 1985, and a JD degree from the Law School at Loyola Marymount, Los Angeles. Between 1989 and 1990, he served as Editor-In-Chief of the Loyola of Los Angeles Law Review. From 1990 to 2002, he practiced law with the firm of Lyon & Lyon LLP, based in Los Angeles, and then, from 2002 to 2015, as a partner with Orrick Herrington & Sutcliffe. Currently, Kurt Mulville is a partner at VLP Law Group.
Terry D. Carlone, JD, Corporate Counsel
Mr Carlone has held leadership, and corporate counsel positions for over 25 years in a number of technology companies, serving as Chief Administrative Officer, and General Counsel at Synergex International Corporation, Chairman and Chief Administrative Officer at Altergy Systems, and Corporate General Counsel at Ventria Bioscience.
Prior to his corporate career, Mr Carlone practiced law with the Sacramento office of McDonough, Holland & Allen, heading the expansion of their tech and biotechnology business, with Weintraub, Genshlea & Sproul as Chairman of the Technology and Intellectual Property Group, and with Pillsbury, Madison & Sutro in San Francisco and Washingotn DC, being one of the three founding attorneys of the DC office in 1980.
Mr. Carlone is founder of Capital Law Group, and the Managing Director of the JAIC/Davis Bioscience Fund. He frequently lectures or serves as panelist on investing in technology-based startups, capital formation, and other issues related to startup and emerging growth companies. He is a member of the State Bar of California, District of Columbia Bar, and Hawaii State Bar Association. Mr Carlone also serves in the Board of Directors of technology and healthcare companies and organizations involved in capital growth and entrepreneurship.
Mr Carlone holds a BA degree from Northwestern University in 1973 and a JD from Georgetown University in 1976.
Alfredo Quattrone, VP of Regulatory Affairs
Dr Quattrone has joined our team in 2009 to provide strategic guidance in regulatory affairs and compliance. Dr Quattrone is leading our efforts in developing and commercializing Milagen first medical device products, namely immunohistochemistry reagents and kits for in vitro diagnostic use. He is also responsible for providing quality system oversight.
After a PhD in Medicinal Chemistry from the University of Pittsburgh in 1970, Dr Quattrone’s academic career developed at the National Cancer Institute of the National Institutes of Health and at the Pathology Department of the University of Texas Health Center in Dallas. From 1980 to 1985, Dr Quattrone turned his career to industry when he joined SmithKline Beckman Corporation as immunochemist and toxicologist Senior Scientist. He then dedicated over 20 years of expertise as Staff Toxicologist at the California (CA) State Food & Drug Branch of the CA Department of Health Services specializing in medical devices, diagnostic kits, FDA third party 510(k) submission and reviews, and quality system inspections and audits.
Dr Quattrone is a member and diplomat of the American Board of Toxicology (DABT), the American Board of Clinical Chemistry (DACC), and has held a CA Clinical Laboratory Scientist license until 1998.
Rosaura P.C. Valle, PhD, VP of Operations & Strategic Alliances
Dr Valle has been with the company since inception, and part of Milagen executive team, since 2001. She has thus contributed to Milagen growth and development from start-up stage to the present, in capacities spanning research, operations and strategic alliances.
Instrumental in developing research proposals and collaborations, Dr Valle has been in charge of government funding applications and clinical sample procurement, and responsible for establishing numerous academic collaborations with clinical centers in the US and abroad.
Dr Valle’s responsibilities encompass various aspects of Milagen product development, as she closely works with Company counsel on Milagen patent portfolio, as well as with Milagen regulatory affairs team on issues regarding medical devices.
Dr Valle received her PhD in Biochemistry and Molecular Biology in 1989 from the University of Paris VII-Denis Diderot in Paris, France. She held post-doctoral and research positions at the National Institute of Digestive and Kidney Diseases (NIDDK) of the NIH, and in the Office of Vaccine Research and Review of the Center for Biologics Evaluation and Research (CBER) of the FDA. She authored peer-reviewed articles in molecular virology, and in the application of Milagen early technologies to biomarker discovery.
Christine Chavany, PhD, RAC, Director of Immunoassay Development
Dr Chavany has led Milagen R&D effort in cancer biomarker discovery and development since inception of the company in 1997. She has been a key figure in the development of all company’s technologies, from antibody screening to biomarker discovery, from monoclonal antibody production to immunoassay development. Dr Chavany has also been Principal Investigator in numerous NIH-SBIR funded projects.
Dr Chavany oversees the GMP manufacturing of Milagen diagnostic product pipeline and provides guidance in regulatory affairs and compliance, closely working with the Regulatory Team.
Dr Chavany received her PhD in Pharmaceutical Sciences from the University of Paris XI-Orsay in 1991, and trained at the National Cancer Institute of the NIH from 1991 to 1997 focusing on the anti-cancer activity of antisense oligonucleotides and drugs, and characterization of transgenic mice as model for neuro-degenerative diseases. Prior to joining Milagen, she held Scientist positions in the biotech sector. Dr Chavany is member of the American Association for Cancer Research (AACR) and is Regulatory Affair Certified by the Regulatory Affair Professional Society since 2001